Premium
P1‐239: FUNCTIONAL CONNECTIVITY BETWEEN THE OLFACTORY NETWORK AND THE HIPPOCAMPUS AS A BIOMARKER FOR ALZHEIMER'S DISEASE DEGENERATION
Author(s) -
Lu Jiaming,
Testa Nicole,
Jordan Rebecca,
Yang Qing S.,
Eslinger Paul,
Karunanayaka Prasanna
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.794
Subject(s) - hippocampus , neuroscience , hippocampal formation , piriform cortex , orbitofrontal cortex , dementia , alzheimer's disease , biomarker , resting state fmri , psychology , cognition , medicine , disease , biology , prefrontal cortex , biochemistry
SPECT [VII, 3-1, 1 abstained]. In patients with suspected Alzheimer’s disease (AD), rachicentesis was voted as the first-choice etiological biomarker [I, 5-0], to be accompanied with FDG-PET if previous MRI was negative [III, 5-0]. In patients over age 75 and consistent clinical and MRI findings, rachicentesis prescription should depend on the plausible clinical impact [IV, 5-0]. AmyloidPET should be prescribed if rachicentesis cannot be performed, or provided borderline inconclusive values. Finally, with suspected Frontotemporal Lobar Degeneration (FTLD) and very low diagnostic confidence of AD, the panelists suggest FDG-PET to assess the pattern of hypometabolism [VII, 4-0, 1 abstained]. Conclusions: We generated consensual recommendations for a cost-effective biomarker-based etiological diagnosis of MCI in memory clinics based on available evidence and expert opinion. These can guide clinicians in the use of biomarkers while the quantitative assessment of their comparative and combined diagnostic value is limited. Acknowledgements: This work was supported by the Italian Health Ministry grant NET-2011-02346784 and the EU-EFPIA Innovative Medicines Initiative 2 Joint Undertaking grant 115952 (AMYPAD).